746 related articles for article (PubMed ID: 29604436)
1. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
Shah N; Mohammad AS; Saralkar P; Sprowls SA; Vickers SD; John D; Tallman RM; Lucke-Wold BP; Jarrell KE; Pinti M; Nolan RL; Lockman PR
Pharmacol Res; 2018 Jun; 132():47-68. PubMed ID: 29604436
[TBL] [Abstract][Full Text] [Related]
2. Current challenges in the management of breast cancer brain metastases.
O'Sullivan CC; Davarpanah NN; Abraham J; Bates SE
Semin Oncol; 2017 Apr; 44(2):85-100. PubMed ID: 28923217
[TBL] [Abstract][Full Text] [Related]
3. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Morikawa A; Peereboom DM; Thorsheim HR; Samala R; Balyan R; Murphy CG; Lockman PR; Simmons A; Weil RJ; Tabar V; Steeg PS; Smith QR; Seidman AD
Neuro Oncol; 2015 Feb; 17(2):289-95. PubMed ID: 25015089
[TBL] [Abstract][Full Text] [Related]
5. Landscape of combination therapy trials in breast cancer brain metastasis.
Fares J; Kanojia D; Rashidi A; Ulasov I; Lesniak MS
Int J Cancer; 2020 Oct; 147(7):1939-1952. PubMed ID: 32086955
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order.
Perez EA
Drug Resist Updat; 2016 Jan; 24():13-22. PubMed ID: 26830312
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
[TBL] [Abstract][Full Text] [Related]
9. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
11. Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Zhang J; Zhang L; Yan Y; Li S; Xie L; Zhong W; Lv J; Zhang X; Bai Y; Cheng Z
Drug Metab Dispos; 2015 Mar; 43(3):411-7. PubMed ID: 25547867
[TBL] [Abstract][Full Text] [Related]
12. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
Tripathy D; Tolaney SM; Seidman AD; Anders CK; Ibrahim N; Rugo HS; Twelves C; Diéras V; Müller V; Du Y; Currie SL; Hoch U; Tagliaferri M; Hannah AL; Cortés J;
JAMA Oncol; 2022 Jul; 8(7):1047-1052. PubMed ID: 35552364
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies for breast cancer brain metastases.
Bailleux C; Eberst L; Bachelot T
Br J Cancer; 2021 Jan; 124(1):142-155. PubMed ID: 33250512
[TBL] [Abstract][Full Text] [Related]
14. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases.
Schlam I; Gatti-Mays ME
Oncologist; 2022 Jul; 27(7):538-547. PubMed ID: 35598254
[TBL] [Abstract][Full Text] [Related]
16. New insights and emerging therapies for breast cancer brain metastases.
Lim E; Lin NU
Oncology (Williston Park); 2012 Jul; 26(7):652-9, 663. PubMed ID: 22888567
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR
Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Duchnowska R; Loibl S; Jassem J
Cancer Treat Rev; 2018 Jun; 67():71-77. PubMed ID: 29772459
[TBL] [Abstract][Full Text] [Related]
19. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Shawky H; Tawfik H
J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
Leone JP; Duda DG; Hu J; Barry WT; Trippa L; Gerstner ER; Jain RK; Tan S; Lawler E; Winer EP; Lin NU; Tolaney SM
Breast Cancer Res Treat; 2020 Jan; 179(1):113-123. PubMed ID: 31541381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]